APP and Alzheimer disease: Changes in the activity of either due to AD-causative mutations in the protein itself (presenilin 1), or mutations in the sequence within APP that is recognised and cleaved by the protein (β-secretase), are associated with enhanced production of Aβ and consequently AD pathogenesis (Hutton and Hardy, 1997; Zhang et al., 2017).